CA-QUOTIENT-SCIENCES
11.8.2020 14:02:03 CEST | Business Wire | Press release
ANA Therapeutics , a Silicon Valley-based biotech startup, and Quotient Sciences , a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005106/en/
Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to safely treat millions of people around the world.
“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski , COO, ANA Therapeutics. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”
Mark Egerton, Ph.D. , CEO of Quotient Sciences, said, “We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic. Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”
Under the scope of the agreement, ANA Therapeutics will access Quotient’s formulation and manufacturing expertise to develop and rapidly supply drug product for pivotal clinical trials in Q3 2020. The program will be conducted at Quotient’s facility in Garnet Valley, Pennsylvania.
About ANA Therapeutics
ANA Therapeutics is a Silicon Valley-based biotech startup working to develop niclosamide as a safe, widely accessible antiviral treatment for patients with COVID-19. A low-cost, scalable, and well-tolerated compound, niclosamide has the potential to be a needed treatment to help individuals who contract the novel coronavirus to beat it.
About Quotient Sciences
Quotient Sciences is an innovative global pharmaceutical development, clinical and commercial manufacturing organization providing services to the pharmaceutical and biotech industries. A combination of specialized skills and agile integrated processes enables Quotient Sciences to develop customized solutions which dramatically reduce the time and cost of getting drugs to market. Everything we do is driven by a deeply held belief, shared across the entire organization, that molecules need to become cures — fast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005106/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
ADM’s Fourth Annual Regenerative Agriculture Report Highlights Growing Resilience Across the Food System15.9.2026 15:00:00 CEST | Press release
2025 programs engaged more than 56,000 farmers across 4.6 million acres in 11 countries ADM (NYSE: ADM), a global leader in innovative solutions from nature, today released its fourth annual regenerative agriculture report, showing how its programs are supporting farmers, strengthening agricultural supply chains and delivering measurable environmental outcomes around the world. “Resilience starts on the farm. By improving and protecting soil health, farmers can be better equipped to adapt to changing conditions and maintain productive operations,” said Greg Morris, SVP and President, Ag Services and Oilseeds, ADM. “That resilience can extend across the value chain, helping strengthen the food system we all depend on.” In 2025, ADM’s regenerative agriculture programs engaged more than 56,000 farmers across approximately 4.6 million acres, 11 countries and 10 crops. Compared with regional benchmarks, the programs resulted in approximately 946,000 metric tons of CO₂e reductions. “ADM view
Diligent Unveils New Agentic Capabilities in Diligent One to Power the Future of Governance, Risk and Compliance15.9.2026 15:00:00 CEST | Press release
New capabilities help organizations move from fragmented information to confident action while keeping people in control Diligent, the AI leader in governance, risk and compliance (GRC) solutions, today announced a major enhancement to Diligent One, its native AI platform, at Gartner’s Enterprise Risk, Audit and Compliance Conference (ERAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915941016/en/ “For many organizations, GRC work is slowed by fragmented systems, manual coordination and time-consuming reporting processes,” said Brian Stafford, President and CEO of Diligent. “Our latest agentic capabilities help teams cut through that complexity by connecting context, surfacing what matters and driving faster execution — while keeping governance and professional judgement at the center." An orchestration agent that coordinates work and approvals The orchestration agent in Diligent One gives GRC professionals a natural-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom